Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.5900 |
Strike | 64.00 |
Expiry date | 2024-05-31 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Thursday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the SUPERNOVA Phase 3 COVID-19 pre-exposure prophylaxis (prevention) trial. The study showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in immunocompromised patients. The trial met both dual primary endpoints: Relative risk reduct
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.